Novo Nordisk Company announced on October 9 that the world’s first and only glucagon-like peptide analogue (human GLP-1 analogue) liraglutide injection (trade name: Novozymes) was officially established Listed in China. This new type of drug for treating type 2 diabetes in adults can effectively solve the risk of hypoglycemia during the process of lowering blood sugar, and at the same time, it can also reduce the body weight and blood pressure of the patient, and it can also protect pancreatic islet β cells.
Novopower has a unique mechanism of action. Yang Wenying, director of the Department of Endocrinology at the China-Japan Friendship Hospital of the Ministry of Health, led the registration study of the drug in China. She said that GLP-1 is a hormone in the gastrointestinal tract that stimulates insulin secretion. This hormone is glucose-dependent and only GLP-1 is activated to function when glucose is elevated. If a person's blood glucose Normally, even if more GLP-1 is injected, it will not be activated. It is also based on this that Novozymes rarely causes hypoglycemia while effectively reducing blood sugar and overcomes the most common adverse reactions in traditional diabetes treatment.
Professor Ji Liongong, chairman of the Diabetes Branch of the Chinese Medical Association and director of the Department of Endocrinology at People's Hospital of Peking University, pointed out that nearly 80% of diabetic patients in China suffer from substandard blood glucose control. In addition to the public’s lack of understanding of diabetes, the diagnosis rate and treatment rate are low. The most common hypoglycemic adverse reactions to the treatment of diabetes are also one of the important causes of difficult blood glucose control.
In the process of research, Novozymes has attracted extensive attention from clinical experts. Even before it was listed, it was recognized by some authoritative academic organizations. In 2008, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) jointly published a newly revised guideline for the treatment of diabetes, which for the first time recognized that GLP-1 receptor agonists are an effective treatment for type 2 diabetes. According to Wan Xin, director of Diabetes Marketing at Novo Nordisk (China) Pharmaceutical Co., Ltd., it is expected that the company will achieve a global sales revenue of over one billion US dollars this year.
The latest survey shows that China has become the world's largest diabetes population, the prevalence of adults over the age of 20 is 9.7%, and there are more than 92.4 million adults with type 2 diabetes. The huge population and rising prevalence rate have made China's diabetes drug market an emerging potential market that major manufacturers have vigorously cultivated and tapped. Through many years of hard work, Novo Nordisk has occupied a leading position in the Chinese diabetes drug market. The listing of Novozymes will further consolidate and strengthen Novo Nordisk’s position in this field. Zhang Kezhou, vice president of the Novo Nordisk (China) Pharmaceutical Department, said that in the face of China's nearly 100 million diabetic patients, education, resources and products are the three most important aspects of diabetes prevention and treatment. Novo Nordisk has invested a lot of power and resources in these three areas. (
Novopower has a unique mechanism of action. Yang Wenying, director of the Department of Endocrinology at the China-Japan Friendship Hospital of the Ministry of Health, led the registration study of the drug in China. She said that GLP-1 is a hormone in the gastrointestinal tract that stimulates insulin secretion. This hormone is glucose-dependent and only GLP-1 is activated to function when glucose is elevated. If a person's blood glucose Normally, even if more GLP-1 is injected, it will not be activated. It is also based on this that Novozymes rarely causes hypoglycemia while effectively reducing blood sugar and overcomes the most common adverse reactions in traditional diabetes treatment.
Professor Ji Liongong, chairman of the Diabetes Branch of the Chinese Medical Association and director of the Department of Endocrinology at People's Hospital of Peking University, pointed out that nearly 80% of diabetic patients in China suffer from substandard blood glucose control. In addition to the public’s lack of understanding of diabetes, the diagnosis rate and treatment rate are low. The most common hypoglycemic adverse reactions to the treatment of diabetes are also one of the important causes of difficult blood glucose control.
In the process of research, Novozymes has attracted extensive attention from clinical experts. Even before it was listed, it was recognized by some authoritative academic organizations. In 2008, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) jointly published a newly revised guideline for the treatment of diabetes, which for the first time recognized that GLP-1 receptor agonists are an effective treatment for type 2 diabetes. According to Wan Xin, director of Diabetes Marketing at Novo Nordisk (China) Pharmaceutical Co., Ltd., it is expected that the company will achieve a global sales revenue of over one billion US dollars this year.
The latest survey shows that China has become the world's largest diabetes population, the prevalence of adults over the age of 20 is 9.7%, and there are more than 92.4 million adults with type 2 diabetes. The huge population and rising prevalence rate have made China's diabetes drug market an emerging potential market that major manufacturers have vigorously cultivated and tapped. Through many years of hard work, Novo Nordisk has occupied a leading position in the Chinese diabetes drug market. The listing of Novozymes will further consolidate and strengthen Novo Nordisk’s position in this field. Zhang Kezhou, vice president of the Novo Nordisk (China) Pharmaceutical Department, said that in the face of China's nearly 100 million diabetic patients, education, resources and products are the three most important aspects of diabetes prevention and treatment. Novo Nordisk has invested a lot of power and resources in these three areas. (
pressure cock valve
Multi-Pass Cock Valve,Cock Valve,Pressure Cock Valve
Zhejiang Haisheng Medical Device Co., Ltd , https://www.hisernmedical.com